Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 11 to 20 of 32

TitleReference numberPublishedLast updated
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770

Results per page

  1. 10
  2. 25
  3. 50
  4. All